Vincent, Kathy and Rich discuss COVID-19 research paper overload, Moderna’s mRNA vaccine Phase I results, increase of ACE2 RNA by cigarette smoke, and answer listener questions.
Daniel Griffin provides a clinical update on COVID-19, then we review results showing requirement for the furin site in the SARS-CoV-2 spike for replication, US state vaccine exemptions, concerns with a rapid diagnostic test, and answers to listener questions.
Vincent, Kathy and Rich explain the Jenner Institute’s SARS-CoV-2 vaccine, the NIH decision to stop the Remdesivir study, and answer listener questions.
Daniel Griffin provides a weekly clinical update on COVID-19, then Michael Schmidt discusses how dentistry can be safely practiced during a pandemic, followed by answers to listener questions.
The TWiV team summarizes serology-based tests for SARS-CoV-2, lack of effect of ACE inhibitors or ARBs on COVID-19 severity, and answers listener questions.
Susan Weiss recalls some of her 40 years of research on coronaviruses, including mouse hepatitis virus, MERS-CoV, and now SARS-CoV-2.
Daniel Griffin updates the clinical situation with COVID-19 patients, followed by analysis of the remedesivir clinical trial results, and answers listener questions.
Jeff Shaman returns to TWiV to explain why more SARS-CoV-2 testing and contact tracing is needed to stop the pandemic, insights on immunity and reinfection from seasonal CoVs, the problems with antibody tests, and what to expect in the coming months.
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.
Ralph Baric, Mark Heise and Nat Moorman discuss their non-profit initiative READDI, Rapidly Emerging Antiviral Drug Discovery Initiative, to start making drugs now for the next pandemic virus.